Human pluripotent stem cells (PSCs) are a promising source of cells for applications in regenerative medicine. Directed differentiation of PSCs into specialized cells such as spinal motoneurons 1 or midbrain dopamine (DA) neurons 2 has been achieved. However, the effective use of PSCs for cell therapy has lagged behind. Whereas mouse PSCderived DA neurons have shown efficacy in models of Parkinson's disease 3, 4 , DA neurons from human PSCs generally show poor in vivo performance 5 . There are also considerable safety concerns for PSCs related to their potential for teratoma formation or neural overgrowth 6, 7 . Here we present a novel floor-plate-based strategy for the derivation of human DA neurons that efficiently engraft in vivo, suggesting that past failures were due to incomplete specification rather than a specific vulnerability of the cells. Midbrain floor-plate precursors are derived from PSCs 11 days after exposure to small molecule activators of sonic hedgehog (SHH) and canonical WNT signalling. Engraftable midbrain DA neurons are obtained by day 25 and can be maintained in vitro for several months. Extensive molecular profiling, biochemical and electrophysiological data define developmental progression and confirm identity of PSCderived midbrain DA neurons. In vivo survival and function is demonstrated in Parkinson's disease models using three host species. Long-term engraftment in 6-hydroxy-dopamine-lesioned mice and rats demonstrates robust survival of midbrain DA neurons derived from human embryonic stem (ES) cells, complete restoration of amphetamine-induced rotation behaviour and improvements in tests of forelimb use and akinesia. Finally, scalability is demonstrated by transplantation into parkinsonian monkeys. Excellent DA neuron survival, function and lack of neural overgrowth in the three animal models indicate promise for the development of cell-based therapies in Parkinson's disease.
Human pluripotent stem cells (PSCs) are a promising source of cells for applications in regenerative medicine. Directed differentiation of PSCs into specialized cells such as spinal motoneurons 1 or midbrain dopamine (DA) neurons 2 has been achieved. However, the effective use of PSCs for cell therapy has lagged behind. Whereas mouse PSCderived DA neurons have shown efficacy in models of Parkinson's disease 3, 4 , DA neurons from human PSCs generally show poor in vivo performance 5 . There are also considerable safety concerns for PSCs related to their potential for teratoma formation or neural overgrowth 6, 7 . Here we present a novel floor-plate-based strategy for the derivation of human DA neurons that efficiently engraft in vivo, suggesting that past failures were due to incomplete specification rather than a specific vulnerability of the cells. Midbrain floor-plate precursors are derived from PSCs 11 days after exposure to small molecule activators of sonic hedgehog (SHH) and canonical WNT signalling. Engraftable midbrain DA neurons are obtained by day 25 and can be maintained in vitro for several months. Extensive molecular profiling, biochemical and electrophysiological data define developmental progression and confirm identity of PSCderived midbrain DA neurons. In vivo survival and function is demonstrated in Parkinson's disease models using three host species. Long-term engraftment in 6-hydroxy-dopamine-lesioned mice and rats demonstrates robust survival of midbrain DA neurons derived from human embryonic stem (ES) cells, complete restoration of amphetamine-induced rotation behaviour and improvements in tests of forelimb use and akinesia. Finally, scalability is demonstrated by transplantation into parkinsonian monkeys. Excellent DA neuron survival, function and lack of neural overgrowth in the three animal models indicate promise for the development of cell-based therapies in Parkinson's disease.
Recent mouse genetic studies have demonstrated an important role for the transcription factor FOXA2 during midbrain DA neuron development 8, 9 . A unique feature of the developing midbrain is the coexpression of the floor-plate (FP) marker FOXA2 and the roof plate marker LMX1A. Normally, FP and roof plate cells are located at distinct positions in the central nervous system (ventral versus dorsal) and show diametrically opposed patterning requirements 10, 11 . We recently reported the derivation of FP precursors from ES cells 12 using a modified dual-SMAD inhibition protocol 13 . Canonical Wnt signalling is important for both roof plate function 14 and midbrain DA neuron development 15 . We therefore proposed that WNT activation may induce LMX1A expression and neurogenic conversion of PSCderived midbrain FP towards DA neuron fate. Here we report that exposure to CHIR99021 (CHIR), a potent GSK3B inhibitor known to strongly activate WNT signalling 16 , induces LMX1A in FOXA21 FP precursors (Fig. 1a ). CHIR was much more potent than recombinant WNT3A or WNT1 at inducing LMX1A expression (data not shown). The efficiency of LMX1A induction was dependent on the timing of CHIR exposure with a maximum effect from day 3 to day 11 (Supplementary Fig. 1 ). CHIR was the most critical factor for inducing coexpression of FOXA2/LMX1A, while other factors such as FGF8 had only marginal effects ( Supplementary Fig. 2 ). Induction of FOXA2/ LMX1A coexpression required strong activation of SHH signalling using purmorphamine, a small molecule agonist, alone or in combination with recombinant SHH ( Supplementary Fig. 3 ). Treatment with SHH agonists (purmorphamine 1 SHH) and FGF8 (S/F8) in the absence of CHIR showed significantly lower expression of FOXA2 by day 11 and complete lack of LMX1A expression ( Fig. 1a, b ). Dual SMAD inhibition (exposure to LDN193189 1 SB431542, 'LSB') did not yield FOXA2-expressing cells, but a subset of LMX1A1 cells ( Fig. 1a, b ). The anterior marker OTX2 was robustly induced in LSB-and LSB/S/F8/CHIR-treated cultures, but not under LSB/S/F8 conditions ( Fig. 1a, c) . Systematic comparisons of the three culture conditions ( Fig. 1d ) were performed using global temporal gene expression profiling. Hierarchical clustering of differentially expressed genes segregated the three treatment conditions by day 11 of differentiation ( Supplementary Fig. 4a ). FOXA1, FOXA2 and several other SHH downstream targets including PTCH1 were among the most differentially regulated transcripts in LSB/S/F8/CHIR versus LSB treatment sets ( Fig. 1e ). Expression of LMX1A, NGN2 (also known as NEUROG2) and DDC indicated establishment of midbrain DA neuron precursor fate already by day 11 (Fig. 1e, f) . In contrast, LSB cultures were enriched for dorsal forebrain precursor markers such as HES5, PAX6, LHX2 and EMX2. Direct comparison of LSB/S/F8/CHIR versus LSB/S/F8 treatment ( Fig. 1f ) confirmed selective enrichment for midbrain DA precursor markers in LSB/S/F8/CHIR group and suggested hypothalamic precursor identity in LSB/S/F8-treated cultures based on the differential expression of RAX, SIX3 and SIX6 (ref. 17) (see also POMC and OTP expression in Fig. 2d below) . The full list of differentially expressed transcripts (Supplementary Tables 1 and 2) and gene ontology analysis ( Supplementary Fig. 4b . 1g ) versus anterior and ventral non-DA fates (Fig. 1h ) partitioned the three induction conditions into (1) LSB: dorsal forebrain; (2) LSB/S/F8: ventral/hypothalamic; (3) LSB/S/F8/CHIR: midbrain DA identity.
By day 25, all three conditions yielded TUJ11 neurons ( Fig. 2a ) and cells expressing TH, the rate-limiting enzyme in the synthesis of DA. However, only the LSB/S/F8/CHIR group yielded TH1 cells coexpressing LMX1A and FOXA2 as well as the nuclear receptor NURR1 (also known as NR4A2) ( Fig. 2a, b ). Comparing gene expression in day 13 versus day 25 cultures confirmed robust induction of postmitotic DA neuron markers ( Fig. 2c ). Characterizing DA neuron identity at day 25 in comparison to LSB and LSB/S/F8 showed enrichment for known 
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midbrain DA neuron transcripts and identified multiple novel candidate markers ( Fig. 2d , Supplementary Tables 3-5 and Supplementary Fig. 4b ). For example, the transcript most highly enriched in LSB/ S/F8/CHIR (midbrain DA group) was TFF3, a gene not previously associated with midbrain DA neuron development, but highly expressed in the human substantia nigra ( Supplementary Fig. 4c ; Allen Brain Atlas http://human.brain-map.org). Similar data were obtained for EBF1, EBF3 ( Supplementary Fig. 4c ) as well as TTR, a known transcriptional target of FOXA2 in the liver 19 . We observed enrichment of several PITX genes, and PITX3, a classic marker of midbrain DA neurons, was also expressed robustly at day 25 of differentiation ( Fig. 2e ). Finally, both midbrain FP and DA neuron induction was readily reproduced in independent ES cell and human induced PSC lines ( Supplementary Fig. 5 ). Our data demonstrate that the LSB/S/F8/CHIR protocol yields cells expressing a marker profile matching midbrain DA neuron fate. We next proceeded to determine the in vitro and in vivo properties of FP-derived DA neurons in comparison to DA neurons obtained via a neural rosette intermediate 3 ( Supplementary Fig. 6 ). Patterning of neural rosettes represents the currently most widely used strategy for deriving DA neurons from PSCs 2,6,20 . Both FP-and rosette-based protocols were efficient at generating TH1 neurons capable of long-term in vitro survival (day 50 of differentiation; Fig. 3a ). However, the percentage of TH1 cells was significantly higher in FP-derived cultures (Fig. 3b ). Whereas TH1 cells in both protocols showed coexpression of NURR1, only FP-derived DA neurons coexpressed FOXA2 and LMX1A ( Fig. 3a,b ). Few GABA-(c-aminobutyric acid) and serotonin (5-HT)-positive neurons were observed ( Fig. 3c ). DA, and its metabolites DOPAC (3,4-dihydroxy-phenylacetic acid )and HVA (homovanillic acid), were present in cultures generated with either protocol, but DA levels were approximately eight times higher in FP cultures ( Fig. 3d, e ). Midbrain DA neurons showed extensive fibre outgrowth and robust expression of mature neuronal markers including synapsin, dopamine transporter (DAT) and G-proteincoupled, inwardly rectifying potassium channel (KCNJ6 (Kir3.2), also called GIRK2), expressed in substantia nigra pars compacta (SNPC) DA neurons ( Fig. 3f and Supplementary Fig. 7 ).
SNPC DA neurons in vivo show an electrophysiological phenotype that differentiates them from most other neurons in the brain. In particular, they spike spontaneously at a slow (1-3 Hz) rate. Moreover, this slow spiking is accompanied by a slow, sub-threshold oscillatory potential 21, 22 . After 2-3 weeks in vitro, these same physiological features are shown by SNPC DA neurons grown from early postnatal mice (data not shown). The DA neurons differentiated from ES cells consistently (4/4) had this distinctive physiological phenotype ( Fig. 3g-i) . Future studies will be required to determine whether all features of SNPC DA neurons are recapitulated by the ES cell DA neurons in vitro or whether full differentiation will require maturation in vivo. However, our data indicate that FP-derived DA neurons do show the cardinal physiological features of mature SNPC DA neurons.
A major challenge in the field has been the ability to generate PSCderived midbrain DA neurons that functionally engraft in vivo without the risk of neural overgrowth 7 or inappropriate differentiation into non-midbrain neurons 23 . On the basis of fetal tissue transplantation studies 24 we proposed that the time of cell cycle exit, marked by expression of NURR1 (ref. 25) , may be a suitable stage for grafting (,day 25 of differentiation, Fig. 2 ). Initial studies using day 25 cells in non-lesioned adult mice showed robust survival of PSC-derived FOXA21/TH1 neurons at 6 weeks after transplantation (Supplementary Fig. 8 ). We next addressed whether FOXA21/TH1 cells survive long-term in parkinsonian hosts without resulting in neural overgrowth. To this end, we made 6-hydroxy-dopamine (6-OHDA) lesions 3 in NOD-SCID IL2Rgc null mice, a strain that efficiently supports xenograft survival with particular sensitivity for exposing rare tumorigenic cells 26 . Both FP-and rosette-derived cultures were grafted (1.5 3 10 5 per animal) without prior purification to reveal potential contaminating cells with proliferative potential. Four and a half months after transplantation FP-derived DA neuron grafts showed a well-defined graft core composed of TH1 cells coexpressing FOXA2 and human-specific NCAM (Fig. 4a-c) . Functional analysis showed a complete rescue of amphetamine-induced rotation behaviour. In contrast, rosette-derived grafts had few TH1 neurons, did not produce significant reductions in rotation behaviour ( Fig. 4d ) and showed massive neural overgrowth (graft volume . 20 mm 3 ; Supplementary  Fig. 9 ). Extensive overgrowth reported here as compared to previous work with rosette-derived DA grafts 27, 28 is likely due to the longer survival periods (4.5 months versus 6 weeks), lack of fluorescenceactivated cell sorting purification before transplantation and choice of NOD-SCID IL2Rgc null host. The number of proliferating Ki-671 cells was minimal in FP-derived grafts (,1% of total cells), while rosette-derived grafts retained pockets of proliferating neural precursors. Neural overgrowth is thought to be caused by primitive anterior neuroectodermal cells within the graft 6, 29 . This hypothesis was supported by the expression of the forebrain marker FOXG1 in rosettederived but not FP-derived grafts. A small percentage of astroglial cells were present in both FP-and rosette-derived grafts, although most GFAP1 cells were negative for human markers, indicating host origin ( Supplementary Fig. 9 ). 
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Our results in NOD-SCID IL2Rgc null mice demonstrated robust long-term survival of FOXA21/TH1 neurons, complete reversal of amphetamine-induced rotation behaviour and lack of neural overgrowth. However, some of these outcomes could be attributable to the specific use of NOD-SCID IL2Rgc null mice. To test this hypothesis, FP-derived DA neuron cultures (2.5 3 10 5 cells) were transplanted in adult 6-OHDA-lesioned rats immunosuppressed pharmacologically using cyclosporine A. Five months after transplantation graft survival was robust ( Fig. 4e-h) with an average of more than 15,000 TH1 cells coexpressing FOXA2 (Fig. 4g ) and human nuclear antigen (Fig. 4e) ; TH1/NCAM1 fibres emanated from the graft core into the surrounding host striatum (Fig. 4f ). In addition to FOXA2, TH1 cells expressed midbrain DA neuron markers PITX3 and NURR1 ( Fig.  4h-j) . Behavioural analyses showed complete rescue of amphetamineinduced rotational asymmetry in contrast to sham-grafted animals (Fig. 4k ). Grafted animals also showed improvements in the stepping test ( Fig. 4l ) measuring forelimb akinesia and in the cylinder test ( Fig. 4m) , assays that do not depend on pharmacological stimulation of the DA system. The late onset of recovery (approximately 3-4 months after transplantation) is expected for human DA neurons and depends on the rate of in vivo maturation including levels of DAT expression (Fig. 4n) . The presence of TH1 cells expressing Kir3.2 channels or calbindin indicate that both SNPC (A9) and ventral tegmental area (A10) DA neurons are present in the graft (Fig. 4o, p) . As in mice ( Supplementary Fig. 9 ), serotonergic and GABAergic cells were rare (,1% of total cells), as were the mostly host-derived GFAP1 glial cells (7% of total cells; Supplementary Fig. 10 ). While few serotonin1 neurons were detected in the graft, we observed human NCAM-negative, likely host-derived serotonergic fibres (Supplementary Fig. 10 ). Our results demonstrate excellent graft survival and behavioural outcome in two independent murine models. However, the number of DA neurons required in a mouse or rat brain represents only a fraction of the cells needed in a human. To test the scalability of our approach, we performed pilot grafting studies in two adult 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned rhesus monkeys. We readily obtained batches of 5 3 10 7 transplantable DA neuron precursors by day 25 of differentiation using the FP-based protocol. Cells were injected at three locations (posterior caudate and pre-commissural putamen) on each side of the brain (six tracts in total, 1.25 3 10 6 cells per tract), and the animals were immunosuppressed with cyclosporine-A. One side of the brain was injected with DA precursors from a green fluorescent protein (GFP)-expressing subclone of H9, while the other side was engrafted with cells derived from unmarked H9 cells. One month after transplantation, we observed robust survival of midbrain DA neurons based on expression of GFP ( Supplementary Fig. 11 ) and the human-specific cytoplasmic 
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marker (SC-121) (Fig. 4q ). Each graft core was surrounded by a halo of TH1 fibres extending up to 3 mm into the host (Fig. 4r ). The graft cores were composed of TH1 neurons coexpressing SC-121 ( Fig. 4s) and FOXA2 (Fig. 4t) . Areas within the graft contained Iba11 host microglia ( Supplementary Fig. 11 ), indicating incomplete immunosuppression.
In conclusion, we present a novel FP-based PSC differentiation protocol that faithfully recapitulates midbrain DA neuron development. Access to cells with the cardinal features of midbrain DA neurons will enable a broad range of biomedical applications such as basic developmental studies, high-throughput drug discovery and Parkinson's disease-iPSC based disease modelling. Importantly, our study establishes a means of obtaining a scalable source of FOXA21/ TH1 neurons for neural transplantation-a major step on the road towards considering a cell based therapy for Parkinson's disease.
METHODS SUMMARY
Human ES cell (H9, H1) and iPSC lines (2C6 and SeV6) were subjected to a modified dual SMAD-inhibition-based 13 FP induction 12 protocol. Exposure to SHH C25II, purmorphamine, FGF8 and CHIR were optimized for midbrain FP and DA neuron yield (see Fig. 1d ). Following FP induction, further maturation was carried out in Neurobasal/B27 medium supplemented with ascorbic acid, BDNF, GDNF, TGFb3 and dibutyryl (db) cyclic AMP (see full methods for details). The resulting DA neurons were subjected to extensive phenotypic characterization via immunocytochemistry, quantitative PCR with reverse transcription (qRT-PCR), gene expression profiling, high-performance liquid chromatography (HPLC) analysis for DA and in vitro electrophysiological recordings. In vivo studies were performed in 6-hydroxydopamine-lesioned, hemiparkinsonian rodents (adult NOD-SCID IL2Rgc mice and Sprague Dawley rats) as well as in two adult rhesus monkeys treated with carotid injections of MPTP. DA neurons were injected stereotactically in the striata of the animals (1.5 3 10 5 cells in mice, 2.5 3 10 5 cells in rats) and a total of 7.5 3 10 6 cells (distributed in six tracts; three on each side of brain) in monkeys. Behavioural assays were performed at monthly intervals after grafting, including amphetamine-mediated rotational analysis as well as a test for focal akinesia ('stepping test') and forelimb use (cylinder test). Rats and mice were killed at 18-20 weeks and the primates at 1 month after grafting. Characterization of the grafts was performed via stereological analyses of cell numbers and graft volumes and comprehensive immunohistochemistry.
METHODS
Culture of undifferentiated ES cells. ES cell lines H9 (WA-09, XX, passages [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] , H1 (WA-01, XY, passages 30-40) and iPS cell lines 2C6 (XY, passages 20-30, ref. 27) and SeV6 (XY, passages 20-30; derived from MRC-5 using non-integrating 4 factor Sendai vector system 30 ) were maintained on mouse embryonic fibroblasts (MEF, Global Stem) in 20% knockout serum replacement (KSR, Invitrogen)containing ES cell medium as described previously 27 . Neural induction. For FP-based midbrain DA neuron induction, a modified version of the dual-SMAD inhibition 13 and FP induction 12 protocol was used based on timed exposure to LDN193189 (100 nM, Stemgent), SB431542 (10 mM, Tocris), SHH C25II (100 ng ml 21 , R&D), Purmorphamine (2 mM, Stemgent), FGF8 (100 ng ml 21 , R&D) and CHIR99021 (CHIR; 3 mM, Stemgent). Note: for the FP induction protocol we refer to 'SHH' treatment as exposure of cells to a combination of SHH C25II 100 ng ml 21 1 purmorphamine (2 mM). Cells were plated (35 3 10 3 -40 3 10 3 cells per cm 2 ) and grown for 11 days on matrigel (BD) in knockout serum replacement medium (KSR) containing DMEM, 15% knockout serum replacement, 2 mM L-glutamine and 10 mM b-mercaptoethanol. KSR medium was gradually shifted to N2 medium starting on day 5 of differentiation as described previously 13 . On day 11, media was changed to Neurobasal/B27/L-Glut containing medium (NB/B27; Invitrogen) supplemented with CHIR (until day 13) and with BDNF (brain-derived neurotrophic factor, 20n ml 21 ; R&D), ascorbic acid (0.2 mM, Sigma), GDNF (glial cell line-derived neurotrophic factor, 20 ng ml 21 ; R&D), TGFb3 (transforming growth factor type b3, 1 ng ml 21 ; R&D), dibutyryl cAMP (0.5 mM; Sigma), and DAPT (10 mM; Tocris,) for 9 days. On day 20, cells were dissociated using Accutase (Innovative Cell Technology) and replated under high cell density conditions (300 3 10 3 -400 3 10 3 cells per cm 2 ) on dishes pre-coated with polyornithine (PO; 15 mg ml 21 )/laminin (1 mg ml 21 )/fibronectin (2 mg ml 21 ) in differentiation medium (NB/B27 1 BDNF, ascorbic acid, GDNF, dbcAMP, TGFb3 and DAPT) until the desired maturation stage for a given experiment.
For rosette-based DA neuron induction we followed our previously described protocols 2 but used dual-SMAD inhibition to accelerate the initial neural induction step. In brief, ES cells were induced towards neural fate by co-culture with irradiated MS5 cells in KSR supplemented with SB431542 and Noggin (250 ng ml 21 ; R&D), from day 2-8 and SHH 1 FGF8 from day 6-11 of differentiation. After 11 days in KSR, neural rosettes were manually isolated and cultured (P1 stage) in N2 medium supplemented with SHH, FGF8, BDNF and ascorbic acid as described previously 2 . After 5-7 days in P1 stage, rosettes were again harvested mechanically and triturated following incubation in Ca 2 /Mg 2 -free Hanks' balanced salt solution (HBSS) for 1 h and replated on PO/laminin/fibronectincoated plates. Patterning with SHH/FGF8 was continued for 7 days at P2 stage followed by final differentiation in the presence of BDNF, ascorbic acid, GDNF, TGFb3 and dbcAMP as described above until the desired maturation stage for a given experiment (typically 5-7 days for transplantation studies or 32 days for in vitro functional studies). Gene expression analyses. Total RNA was extracted during differentiation at days 0, 1, 3, 5, 7, 9, 11, 13 and 25 from each condition of control LSB, LSB/SHH/FGF8 and LSB/SHH/FGF8/CHIR using an RNeasy kit (Qiagen). For microarray analysis, total RNA was processed by the MSKCC Genomic core facility and hybridized on Illumina Human ref-12 bead arrays according to the specifications of the manufacturer. Comparisons were performed among each days and conditions using the LIMMA package from Bioconductor (http://www.bioconductor.org). Genes found to have an adjusted P-value ,0.05 and a fold change greater than two were considered significant. Some of the descriptive microarray data analyses and presentation was performed using a commercially available software package (Partek Genomics Suite (version 6.10.0915)). For qRT-PCR analyses, total RNA at day 25 of each condition was reverse transcribed (Quantitech, Qiagen) and amplified material was detected using commercially available TaqMan gene expression assays (Applied Biosystems) with the data normalized to HPRT. Each data point represents nine technical replicates from three independent biological samples. Raw data of all the microarray studies are available at GEO http://www.ncbi.nlm. nih.gov/geo/ accession number GSE32658. Animal surgery. All rodent and monkey procedures were performed following NIH guidelines, and were approved by the local Institutional Animal Care and Use Committee (IACUC), the Institutional Biosafety Committee (IBC) as well as the Embryonic Stem Cell Research Committee (ESCRO).
Mice: NOD-SCID IL2Rgc null mice (20-35 g; Jackson Laboratory) were anaesthetized with ketamine (90 mg kg 21 ; Akorn) and xylazine (4 mg kg 21 ). 6-hydroxydopamine (10 mg 6-OHDA, Sigma-Aldrich) was injected stereotactically into the striatum at the following coordinates (in millimetres): AP, 0.5 (from bregma); ML, 22.0; DV, 23.0 (from dura). Mice with successful lesions (an average of .6 rotations per minute) were selected for transplantation. A total of 1.5 3 10 5 cells were injected in a volume of 1.5 ml into the striatum at the following coordinates (in mm): AP, 0.5; ML, 21.8; DV, 3.2. The mice were killed 18 weeks after transplantation.
Rats: adult female Sprague Dawley (Taconic) rats (180-230 g) were anaesthetized with Ketamine (90 mg kg 21 ) and xylazine (4 mg kg 21 ) during surgical procedures. Unilateral, medial forebrain bundle lesions of the nigro-striatal pathway were established by stereotaxic injection of 6-OHDA (3.6 mg ml 21 in 0.2% ascorbic acid and 0.9% saline, Sigma) at two sites 31 . Rats were selected for transplantation if amphetamine-induced rotation exceeded 6 rotations per min by 6-8 weeks post injection. 2.5 3 10 5 cells were transplanted into the striatum of each animal (Coordinates: AP 1.0 mm, ML 22.5 mm and V 24.7 mm; toothbar set at 22.5). Control rats received PBS instead. The surgical procedures were described previously 31 . Daily intraperitoneal injections of cyclosporine 15 mg kg 21 (Bedford Labs) were started 24 h before cell grafting and continued until death, 20 weeks following cell grafting.
Primates: two adult (17-18 year old; 10-12 kg; female) rhesus monkeys were rendered hemiparkinsonian via carotid MPTP administration followed by weekly intravenous MPTP administration to create a bilateral parkinsonian syndrome 32 . Both animals displayed parkinsonian symptoms consistent with a moderatelysevere lesion. On the day of transplantation surgery, animals were tranquilized with ketamine (3.0 mg kg 21 , intramuscular) and dexdomitor (0.02-0.04 mg kg 21 intramuscular), intubated to maintain a stable airway and anaesthetized with isoflurane. They were then placed into a stereotaxic frame for surgery. Both rhesus monkeys underwent a single surgery with three intracranial injections of human FP-derived DA cultures based on stereotaxic coordinates 33 . Bilateral injections of cells (10 ml/injection; 125,000 cells per ml) were performed at three sites (one posterior caudate, two pre-commissural putamen and overlying white matter) for a total volume of 30 ml per hemisphere. An infusion pump attached to a stereotaxic micromanipulator was used to deliver the cells at a rate of 1 ml min 21 though a 50-ml Hamilton syringe with 28 G needle. After the injections were completed, the needle was left in place for an additional 2-5 min to allow the infusate to diffuse off the needle tip before slowly retracting the syringe. Immediately following surgery, the animals received analgesics (buprenex, 0.01 mg kg 21 intramuscular, BID for 72 h post surgery; meloxicam, 0.1 mg kg 21 subcutaneous, SID for 72 h post surgery) as well as an antibiotic (cephazolin, 25 mg kg 21 intramuscular, BID) until 72 h post-surgery. The animals received cyclosporine A (Neoral, Sandimmune) orally (30 mg kg 21 tapered to 15 mg kg 21 ) once daily beginning 48 h before surgery until death, one month following transplantation. Behavioural assays. Amphetamine-induced rotations (mice and rats) and the stepping test (rat) were carried out before transplantation and 4, 8, 12 and 18 weeks after transplantation. Rotation behaviour in mice was recorded 10 min after intraperitoneal injection of d-amphetamine (10 mg kg 21 , Sigma) and recorded for 30 min. Rotation behaviour in rats was recorded 40 min after intraperitoneal injection of d-amphetamine (5 mg kg 21 ) and automatically assessed by the TSE VideoMot2 system (Germany). The data were presented as the average number of rotations per minute. The stepping test was modified from 34, 35 . In brief, each rat was placed on a flat surface, its hind legs were lifted by gently holding up the tail to allow only the forepaws to touch the table. The experimenter pulled the rat backwards 1 m at a steady pace. Adjusting step numbers from both contralateral and ipsilateral forepaws were counted. Data was presented as the percentage of contralateral/(contralateral 1 ipsilateral) adjusting steps. The cylinder test was performed by placing each animal in a glass cylinder and counting the number of ipsilateral versus contralateral paw touches (out of 20 touches) to the wall of the cylinder as described previously 3 . Tissue processing. Mice and rats received overdoses of pentobarbital intraperitoneally (50 mg kg 21 ) to induce deep anaesthesia and were perfused in 4% paraformaldehyde (PFA). Brains were extracted, post-fixed in 4% PFA then soaked in 30% sucrose solutions for 2-5 days. They were sectioned on a cryostat after embedding in O.C.T. (Sakura-Finetek).
Primates were killed under deep anaesthesia with ketamine (10 mg kg 21 , intramuscular) and pentobarbital (25 mg kg 21 , intravenous) via cardiac perfusion with heparinized 0.9% saline followed by fresh cold 4% PFA fixative (pH 7.4). Immediately following primary fixation, brains were removed from the skull and post-fixed in 4% PFA, free-floating, for 24-36 h. They were then rinsed and re-suspended in 10% sucrose on a slow shaker at 4 uC, and allowed to 'sink'. The process was then repeated in 20% sucrose followed by 30% sucrose. Whole brains were cut coronally into 40 mm serial sections on a frozen sledge microtome and stored free-floating in cryopreservative medium at 220 uC. Immunohistochemistry. Cells were fixed in 4% PFA and blocked with 1% BSA with 0.3% Triton. Brain tissue sections were washed in cold PBS and processed similarly. Primary antibodies were diluted in 1-5% BSA or Normal Goat Serum and incubated according to manufacturer recommendations. A comprehensive list of antibodies and sources is provided as Supplementary Table 6 . Appropriate
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